Printer Friendly

CALGENE AND MONSANTO EXECUTE BROAD CROSS LICENSE AGREEMENTS

 DAVIS, Calif., April 23 /PRNewswire/ -- Comprehensive Agreements Between The Premier Agricultural Biotechnology Companies Strengthens Proprietary Positions, Expedites Product Introductions.
 Calgene Inc. (NASDAQ-NMS: CGNE) today announced the signing of several cross licensing agreements with Monsanto Co. (NYSE: MTC) of St. Louis. The agreements resolve several current and potential patent conflicts between the two leading agricultural biotechnology research companies. Under the agreement, Calgene received licenses to Monsanto's patents and patents pending in the areas of plant transformation technologies, selectable markers and the right to obtain certain licenses to Monsanto's Bacillus thuringiensis (Bt) insect resistance technology for use in cotton. Monsanto received licenses to Calgene's patents and patents pending in the areas of plant transformation, certain genetically engineered plants and antisense RNA technology. Calgene and Monsanto granted each other licenses to certain of their respective patents pending in the area of ethylene repression, and settled an interference proceeding at the U.S. Patent Office directed toward CaMV promoters, which are broadly used by agricultural biotechnology companies to control gene expression in genetically engineered plants.
 "This agreement between the leaders in ag biotech will enable both of us to focus on commercializing our products, rather than engaging in costly litigation," said Roger Salquist, Calgene's chief executive officer. "An important objective for both Calgene and Monsanto, which these agreements achieved, was to assure timely commercialization of our first genetically engineered products," said Salquist.
 Monsanto is the first licensee of Calgene's antisense patent estate, including its issued U.S. antisense patent. The U.S. patent, which issued in April 1992, covers the use of antisense RNA in plants, regardless of plant species. Similar coverage is pending worldwide.
 Calgene is an agribusiness biotechnology company that is developing improved plant varieties and plant products for the fresh tomato, cotton seed and specialty industrial and edible oils businesses.
 -0- 4/23/93
 /CONTACT: R. Salquist of Calgene, 916-753-6313/
 (CGNE MTC)


CO: Calgene Inc.; Monsanto Co. ST: California, Missouri IN: MTC SU: LIC

LH-GT -- SF005 -- 9960 04/23/93 10:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1993
Words:332
Previous Article:NEW ICE CREAM JUST FOR KIDS; EDY'S GRAND ICE CREAM INTRODUCES MEGA MOUTH
Next Article:RATE INCREASE FOR COSE HEALTH PLANS IS LOWEST EVER; AVERAGE RISE OF 5.8 PERCENT IS LESS THAN ONE-THIRD OF NON-COSE CLEVELAND MARKET AVERAGE
Topics:


Related Articles
CALGENE ESTABLISHES TREHALOSE PROGRAM
CALGENE SIGNS ANTISENSE PATENT LICENSE WITH THE FRED HUTCHINSON CANCER RESEARCH CENTER
CALGENE ACCESSES TRANSWITCH TECHNOLOGY FROM DNAP
MONSANTO TO ACQUIRE 49.9% EQUITY STAKE IN CALGENE
CALGENE COMPLETES STRATEGIC ALLIANCE WITH MONSANTO
Calgene and Kirin Sign Cross License Agreement
Calgene Board Forms Special Committee to Review Monsanto Proposal
Court of Appeals Affirms Victory for Aventis CropScience On Glyphosate Tolerant Corn.
Dow AgroSciences (Dow) and Monsanto announce a global business agreement that establishes cooperative arrangements.
Bayer CropScience and Monsanto enter long-term business and license agreements for key enabling technologies agreements creating new choices and more...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters